GSK
GSK (NYSE)
GSK stands out as a defensive healthcare stock, benefiting from non-discretionary demand and strong availability in the UK. With a solid dividend yield of 3.67% and impressive returns of 28.86% over the past year, it presents an attractive option for investors seeking reliable income. However, recent analyst ratings reflect caution, with Barclays and Jefferies downgrading their assessments to Underweight and Hold, respectively, despite a median price target of $53.00.
Pros:
- Strong 1-year and 5-year returns
- Defensive healthcare stock
Cons:
- Recent downgrades from analysts
- Market competition in pharmaceuticals
GSK may be suitable for conservative investors looking for a defensive stock in the healthcare sector, particularly those prioritizing steady income through dividends. However, potential investors should weigh the recent analyst downgrades against the stock's historical performance and current market conditions before making a decision.